A process for the preparation of Abaloparatide or pharmaceutically acceptable salts. Also described is pure Abaloparatide or pharmaceutically acceptable salts thereof obtained from the process for the preparation of Abaloparatide.

A method for creating a stable protein/antibody ionic liquid, comprising: (a) cationizing aqueous proteins/antibodies by addition of an excess of a positively-charged crosslinker in the presence of a coupling reagent; (b) purifying the cationized proteins/antibodies; (c) titrating the cationized proteins/antibodies with a corresponding biologically-compatible counter anionic polymer to create at least one protein/antibody cation/anion pair in aqueous solution until the cation/anion pair solution becomes negative by zeta potential measurement; (d) repeatedly dialyzing the protein/antibody cation/anion pair in water to remove excess anionic polymer using at least one molecular weight cutoff 7000 dialysis membrane; (e) lyophilizing the protein/antibody cation/anion pair to remove most of the water, forming a lyophilized solid; and (f) heating the lyophilized solid until a protein/antibody ionic liquid is generated. The antibody may be any desired antibody, and the anion may be any biologically-compatible anion.

A method for creating a stable protein/antibody ionic liquid, comprising: (a) cationizing aqueous proteins/antibodies by addition of an excess of a positively-charged crosslinker in the presence of a coupling reagent; (b) purifying the cationized proteins/antibodies; (c) titrating the cationized proteins/antibodies with a corresponding biologically-compatible counter anionic polymer to create at least one protein/antibody cation/anion pair in aqueous solution until the cation/anion pair solution becomes negative by zeta potential measurement; (d) repeatedly dialyzing the protein/antibody cation/anion pair in water to remove excess anionic polymer using at least one molecular weight cutoff 7000 dialysis membrane; (e) lyophilizing the protein/antibody cation/anion pair to remove most of the water, forming a lyophilized solid; and (f) heating the lyophilized solid until a protein/antibody ionic liquid is generated. The antibody may be any desired antibody, and the anion may be any biologically-compatible anion.

The current invention pertains compositions and methods to generate compositions providing stability to biomolecules, including providing physiologically stable and functional DNA origami-based drug/gene delivery carriers by surface coating with the oligo-ethylene glycol conjugated peptoids of Formulas (I), (II), and (III).

The current invention pertains compositions and methods to generate compositions providing stability to biomolecules, including providing physiologically stable and functional DNA origami-based drug/gene delivery carriers by surface coating with the oligo-ethylene glycol conjugated peptoids of Formulas (I), (II), and (III).

The present invention relates to the processes for preparing glucagon-like peptide-1 (glp-1) receptor agonists and their analogs. The present invention further relates to processes for preparing liraglutide, D-liraglutide, semaglutide and D-semaglutide. The present invention specifically relates to processes for preparing glucagon-like peptide-1 (glp-1) agonist and their analogs, wherein the liraglutide, D-liraglutide, semaglutide and D-semaglutide produced are substantially pure. The present invention also relates to preparation of glucagon-like peptide-1 (glp-1) agonist and their analogs by solid and solution phase method.

The present invention relates to the processes for preparing glucagon-like peptide-1 (glp-1) receptor agonists and their analogs. The present invention further relates to processes for preparing liraglutide, D-liraglutide, semaglutide and D-semaglutide. The present invention specifically relates to processes for preparing glucagon-like peptide-1 (glp-1) agonist and their analogs, wherein the liraglutide, D-liraglutide, semaglutide and D-semaglutide produced are substantially pure. The present invention also relates to preparation of glucagon-like peptide-1 (glp-1) agonist and their analogs by solid and solution phase method.

The present invention relates to Bicycle toxin conjugates, methods for preparation, and methods of use for treating cancer.

The present invention relates to Bicycle toxin conjugates, methods for preparation, and methods of use for treating cancer.

The invention relates to a method for preparing peptides comprising the step of forming a peptide bond wherein the carboxyl group of a first amino acid or first peptide is activated and an amino group of the first activated amino acid or first peptide is protected by a protecting group having a water-solubility enhancing group and the activated carboxyl group of the first amino acid or first peptide is reacted with an amino group of a second amino acid or second peptide wherein said carboxyl group of the first amino acid or first peptide is activated in the absence of the second amino acid or second peptide. The invention further relates to peptides comprising a protecting group having a water-solubility enhancing group being bound to the amino group and an activated or free carboxyl group.